PTD-DBM
Also known as: Hair growth peptide, Peptídeo de crescimento capilar, Protein Transduction Domain-DBM
Molecular Identifiers
Overview
Fusion peptide composed of a protein transduction domain (PTD) conjugated to the Dishevelled binding motif (DBM). Designed to activate the Wnt/β-catenin signaling pathway, essential for hair follicle regeneration and follicular stem cell activation. Researched as an innovative approach for alopecia and hair regeneration.
Fusion peptide — protein transduction domain fused to the Dishevelled binding motif
Half-life
~3-6 hours
Administration Route
Topical or subcutaneous
Category
Specialized Research
Mechanism of Action
- Activation of the Wnt/β-catenin signaling pathway via competitive inhibition of the CXXC5-Dvl interaction
- Hair follicle regeneration and neogenesis
- Activation of follicular stem cells in the bulge region
- Promotion of catagen-to-anagen transition in the hair cycle
- Stimulation of dermal papilla cell proliferation
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-5 mg per application (topical or subcutaneous in the scalp) |
| Frequency | Once daily (topical) or 2-3 times per week (subcutaneous) |
| Timing | Evening for topical application |
| Duration | 4-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Local irritation
- Redness
- Skin sensitivity
Presentations & Preparation
Vials of PTD-DBM found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved — never shake
- For topical use, may be mixed in a suitable vehicle
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 14 days)
- Protect from direct light
- Do not freeze after reconstitution
- Keep sterile for injectable use
Scientific Studies
Published studies on PTD-DBM.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily